KHB(SZ:002022) Sou Hu Cai Jing·2025-04-10 08:47Group 1 - The core viewpoint of the news is that Kehua Bio's stock has shown a slight increase, with a closing price of 5.38 yuan and a market capitalization of 2.767 billion yuan, despite a significant decline in revenue and net profit in the latest financial report [1] - On April 10, 2024, Kehua Bio experienced a net inflow of 936,200 yuan in main funds, indicating a positive trend in fund flow over the past five days, totaling an inflow of 823,600 yuan [1] - Kehua Bio specializes in the research, production, and sales of in vitro diagnostic reagents and medical testing instruments, with its products primarily used in clinical hospital testing and blood donation screening [1] Group 2 - The latest financial results for Kehua Bio show a revenue of 1.35 billion yuan for the third quarter of 2024, representing a year-on-year decrease of 29.09%, and a net loss of approximately 122.14 million yuan, a decline of 512.11% compared to the previous year [1] - The company's gross profit margin stands at 40.04%, indicating its ability to maintain profitability despite the decline in revenue [1] - In comparison to industry averages, Kehua Bio's price-to-earnings (PE) ratio is significantly lower at -8.23, while the industry average PE is 46.15, highlighting the company's underperformance relative to its peers [2]